Article Text

SAT0199 An estimate of the proportion of patients with sle receiving off-label treatment with rituximab in european countries
  1. R. van Vollenhoven1,
  2. M. Seddighzadeh1,
  3. S. Jacobsen2,
  4. T. Dörner3,
  5. G. Ferraccioli4,
  6. F. Houssiau5,
  7. T. Huizinga6,
  8. D. Isenberg7,
  9. K. Lászlό8,
  10. G. Ruiz-Irastorza9,
  11. D. Squatrito10,
  12. A. Voskuyl11,
  13. A. Askanase12,
  14. S. Bernatsky13
  15. for the IRBIS-EMA Study Group
  1. 1Medicine, Karolinska Institute, Stockholm, Sweden
  2. 2Rheumatology, Rigshospitalet, Copenhagen, Denmark
  3. 3Medicine, Charite University Hospitals, Berlin, Germany
  4. 4Divisions of Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
  5. 5Rheumatology, Catholic University of Louvain, Brussels, Belgium
  6. 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands
  7. 7Centre for Rheumatology, University College London, London, United Kingdom
  8. 8Rheumatology, University of Szeged, Szeged, Hungary
  9. 9Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain
  10. 10Clinical Immunology, Careggi Hospital-Florence, Florence, Italy
  11. 11Rheumatology, VU University Medical Center, Amsterdam, Netherlands
  12. 12Rheumatology, Seligman Center for Advanced Therapeutics, New York, United States
  13. 13Division of Clinical Epidemiology, Research Institute of the McGill Univ. Health, Montreal, Canada


Background Rituximab (MabThera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients. There clearly is off-label use of this medication in practice in Europe, but the extent of it has not previously been analyzed. The International Registry for Biologics in SLE (IRBIS), initiated by the SLICC group provided the data for this study.

Objectives To estimate the proportion of SLE patients treated with RTX in Europe.

Methods Data previously submitted to the IRBIS registry by 28 centers in 11 European countries were complemented with additional clinical information from the participating sites and SLE prevalence estimates based on previously published data and data provided by direct contact with participating physicians. For the remaining countries in the European Union (EU) and European Economic Area-European Free Trade Association (EEA-EFTA), estimates were extrapolated on the assumption of regional similarities between countries.

Results Most of the SLE-dedicated rheumatology specialty centers represented in this study had 200 to 300 SLE patients of whom generally <5% were treated with RTX. In the 11 European countries and regions represented in this report the estimated calculated rate of exposure to RTX among SLE patients ranged from 0.6-1.6%. Extrapolating to all 30 EU-EEA-EFTA countries, with an overall population of around 416 million, and with published prevalence estimates for SLE between 3.6 and 7.3 per 10.000 adults, we calculated that between 0.5 and 1.3% of European patients with SLE currently have been treated, off-label, with RTX.

Conclusions In Europe, RTX is estimated to be used off-label in 0.5-1.3% of SLE patients. This modest number suggests that it is chosen only for those patients in whom established therapeutic options have been exhausted. Limitations of the study include the use of extrapolations, and the fact that RTX use by non-rheumatologists was not ascertained. Although controlled evidence for the efficacy of RTX in SLE is lacking, the current usage of RTX in SLE may be considered conservative, given the high medical need in the larger SLE patient population.

Supported by a research grant from Roche

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.